AUA 2021 Prostate Cancer In-depth

Androgen Deprivation Therapy Exposure Linked to Increased Risk of Dementia After Prostate Cancer

ADT exposure after prostate cancer treatment is associated with the onset of dementia.

Pembrolizumab and Olaparib Combination Therapy Shows Antitumor Activity and Acceptable Safety for Pretreated mCRPC

The nonrandomized, multicenter, multicohort, open-label, phase 1b/2 KEYNOTE-365 trial evaluated the safety, tolerability, and efficacy of pembrolizumab combination therapy in men with mCRPC.

Real-World Apalutamide and Enzalutamide Rate of Treatment Discontinuation From AEs Higher Than in Clinical Trials for nmCRPC

Treatment discontinuation from adverse events in real-world use is 32% higher for apalutamide and 49% higher for enzalutamide than reported in clinical trials of patients with non-metastatic castration-resistant prostate cancer.

Castration Resistance-Free Survival With Relugolix vs Leuprolide in Advanced Prostate Cancer

CRFS after relugolix was not significantly different compared with leuprolide in men with advanced prostate cancer and metastatic disease.

Radiotherapy for Prostate Cancer Associated With Long-Term Complications

RT for prostate cancer is associated with distinct treatment-related complications such as cystitis and urinary stricture.